, ?lng=FR&data_id=703&Disease_Disease_Search_di seaseGroup=behcet&Disease_Disease_Search_diseaseType=Pat&Maladie(s )/groupes%20de%20maladies=Maladie-de-Behcet&title=Maladie-de-Behcet&search=Disease_Search_Simple, Maladie de Behcet
Maladie de Behçet : Vascularites, Rev Prat, vol.58, issue.5, pp.533-573, 2008. ,
Uveitis scoring system, Uveitis Scoring System ,
Epidemiology of Behçet Disease, Ocul Immunol Inflamm, vol.20, issue.5, pp.324-359, 2012. ,
A family study of Behcet's syndrome. Ann Rheum Dis, vol.37, pp.459-65, 1978. ,
Behcet's Syndrome, Drugs. 3 déc, vol.72, issue.17, pp.2223-2264, 2012. ,
, Orphanet: À propos des maladies rares
New Insights in the Clinical Understanding of Behçet's Disease, Yonsei Med J. 1 janv, vol.53, issue.1, pp.35-42, 2012. ,
Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany -current pathogenetic concepts and therapeutic possibilities, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. janv, vol.4, issue.1, pp.49-64, 2006. ,
Behçet's disease: a review, J Dent Res. mars, vol.84, issue.3, pp.209-231, 2005. ,
Epidemiology of Behçet's Syndrome and Regional Differences in Disease Expression, Yaz?c? Y, Yaz?c? H, éditeurs. Behçet's Syndrome ,
,
Adult Behcet's disease in Iran: analysis of 6075 patients, Int J Rheum Dis. août, 2015. ,
Behçet's disease leaves the silk road, Adv Dermatol Allergol, vol.6, pp.417-437, 2014. ,
Behçet's disease, Orphanet J Rare Dis, vol.7, issue.1, p.20, 2012. ,
Shafer's Textbook of Oral Pathology, vol.1001, 2014. ,
, Rev Med Suisse, pp.728-761, 2008.
Chronic severe uveitis: classification, search for etiology and therapeutic approach. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, déc, vol.24, issue.12, pp.794-802, 2003. ,
, Haute-vision
,
Behcet's Disease with Uveitis in Taiwan, J Chin Med Assoc, vol.71, issue.10, pp.509-525, 2008. ,
Subclinical atherosclerosis in Behcet's disease: A systematic review and meta-analysis, Semin Arthritis Rheum Fev, vol.45, issue.4, pp.502-512, 2016. ,
Cardiac manifestations in Behcet disease, Intractable Rare Dis Res, vol.4, issue.2, pp.70-75, 2015. ,
Gastrointestinal Behçet's disease: A review, World J Gastroenterol, vol.21, issue.13, p.3801, 2015. ,
Behçet's disease -a contemporary review, J Autoimmun. mai, vol.32, issue.3-4, pp.178-88, 2009. ,
Behcets Syndrome: Literature Review, Curr Rheumatol Rev. 1 févr, vol.5, issue.1, pp.64-82, 2009. ,
The dermatoscopy in the skin pathergy testing: case series in patients with suspected Behçet's Disease. Rev Bras Reumatol Engl Ed, vol.54, pp.494-502, 2014. ,
Innate Immune System of Skin and Oral Mucosa : Properties and Impact in Pharmaceutics, Cosmectifs and Personal Care Products, Arch Dermatol Res, vol.155, p.p, 2010. ,
EULAR recommendations for the management of Behcet disease, Ann Rheum Dis. 1 déc, vol.67, issue.12, pp.1656-62, 2008. ,
The Behcet's disease activity index, Rheumatol Oxf Engl. janv, vol.43, issue.1, pp.73-81, 2004. ,
Disease Assessment in Behçet's Disease, Yaz?c? Y, Yaz?c? H, éditeurs. Behçet's Syndrome ,
What affects the quality of life in patients with Behcet's disease?, Acta Reumatol Port. mars, vol.39, issue.1, pp.46-53, 2014. ,
Behçet's Disease: From Genetics to Therapies, vol.183, 2014. ,
Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab, Jpn J Ophthalmol. mars, vol.58, issue.2, pp.120-150, 2014. ,
, Eye and Behçet new therapeutics perspective
,
Rôle des cellules Th17 dans les maladies infectieuses et auto-immunes, Ann. Méd. Vét, pp.104-116, 2010. ,
Up-regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity, Clin Exp Rheumatol. juin, vol.31, issue.3, pp.32-40, 2013. ,
Immunopathogenesis of Ocular Behçet's Disease, J Immunol Res, vol.2014, pp.1-13, 2014. ,
,
HLA-B51/B5 and the risk of Behçet's disease: A systematic review and metaanalysis of case-control genetic association studies, Arthritis Rheum, vol.61, issue.10, pp.1287-96, 2009. ,
Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy, Mediators Inflamm, vol.2014, pp.1-14, 2014. ,
Les manifestations ophtalmologiques au cours de la maladie de Behçet ( à propos de 33 cas). Faculté de Médecine de Fès, 2011. ,
Pathophysiology of the Behçet's Disease, Pathol Res Int, vol.2012, pp.1-11, 2012. ,
Evaluation of current therapeutic strategies in Behçet's disease, Clin Rheumatol. févr, vol.30, issue.2, pp.157-63, 2011. ,
Anti-inflammatory action of corticosteroids, Postgrad Med J. oct, vol.52, issue.612, pp.631-634, 1976. ,
Current and future treatments for Behçet's uveitis: road to remission, Int Ophthalmol. avr, vol.34, issue.2, pp.365-81, 2014. ,
A controlled trial of azathioprine in Behçet's syndrome, N Engl J Med. 1 févr, vol.322, issue.5, pp.281-286, 1990. ,
Therapy of ocular Behçet disease, Ocul Immunol Inflamm. févr, vol.22, issue.1, pp.64-76, 2014. ,
Treatment of Behcet's Disease, Yonsei Med J, vol.38, issue.6, pp.401-411, 1997. ,
, Résumé des Caractéristiques du Produit PROGRAF
, Notice patient AZATHIOPRINE, p.51
Lyn is a redox sensor that mediates leukocyte wound attraction in vivo, Nature, vol.480, issue.7375, pp.109-121, 2011. ,
Behçet's syndrome: a critical digest of the 2013-2014 literature, Clin Exp Rheumatol. août, vol.32, issue.4, pp.112-122, 2014. ,
, Notice patient COLCHICINE
THE MECHANISM OF ACTION OF ALKYLATING AGENTS, Cancer Res. sept, vol.23, pp.1315-1348, 1963. ,
Immunopathologie et réactions inflammatoires, vol.316, 2003. ,
Treatment of Behçet's syndrom. Peter A merkel, 2009. ,
Management of sight-threatening uveitis: new therapeutic options, Drugs, vol.65, issue.4, pp.497-519, 2005. ,
Current concepts in the etiology and treatment of Behçet disease, Surv Ophthalmol. août, vol.50, issue.4, pp.297-350, 2005. ,
A review of thalidomide's history and current dermatological applications, Dermatol Online J. août, vol.9, issue.3, p.5, 2003. ,
, Autorité de Santé adoptant la recommandation relative à la prise en charge à titre dérogatoire du thalidomide (THALIDOMIDE CELGENE 50 mg, gélule) dans le cadre d'une recommandation temporaire d'utilisation, Haute Autorité de Santé -DECISION N° 2015.0155/DC/SEM du 17 juin 2015 du collège de la Haute
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial, Ann Intern Med. 15 mars, vol.128, issue.6, pp.443-50, 1998. ,
,
Recombinant antibodies for cancer therapy: methods and protocols, Methods in molecular biology, vol.481, 2003. ,
Behçet disease, sarcoidosis, VKH, Acta Ophthalmol (Copenh). sept, vol.90, pp.0-0, 2012. ,
Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model, J Dermatol Sci, vol.52, issue.2, pp.87-97, 2008. ,
Les biothérapies immunomodulatrices du futur : quelles perspectives ? Presse Médicale, vol.38, pp.749-60, 2009. ,
Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients, Semin Arthritis Rheum. août, vol.41, issue.1, pp.61-70, 2011. ,
Adalimumab therapy for refractory uveitis: a pilot study, J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. juin, vol.24, issue.3, pp.351-61, 2008. ,
Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study, Ocul Immunol Inflamm. 24 août, pp.1-8, 2015. ,
Potential benefits of pentoxifylline on wound healing, Expert Rev Clin Pharmacol. janv, vol.9, issue.1, pp.129-171, 2016. ,
les phosphodiestérases des nucléotides cycliques, MédecineSciences. déc, vol.9, issue.12, 1993. ,
Mucocutaneous Lesions of Behçet's Disease, Yonsei Med J, vol.48, issue.4, p.573, 2007. ,
Results of interferon alpha-2a therapy in patients with Behcet's disease, J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. août, vol.28, issue.4, pp.439-482, 2012. ,
, Iridotomie laser et glaucome
Potential Infectious Etiology of Behçet Disease, Potential Infectious Etiology of Behçet Disease, Pathol Res Int Pathol Res Int. 29 déc, p.595380, 2011. ,
, Code de la santé publique -Article L1121-1, 2016.
, LEEM. Les grandes étapes de la vie d'un médicament
, Etudes cliniques, 20 questions, p.81
, Sanofi -Essais cliniques : les phases
,
, pdf/d29861b8-30a7-456e-9a83-508f14f4e6d5
, WMA Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects
, Les bonnes pratiques cliniques: directives consolidées
, Lignes directrices relatives aux Bonnes Pratiques Cliniques (BPC) pour l'essai des médicaments
, ClinicalTrials -Abatacept in the Treatment of Uveitis
Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome ,
Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study ,
, ClinicalTrials -Anakinra for Behcet's Disease
, Anakinra for resistant Behçet uveitis: why not?
, a Human Monoclonal Anti-IL-12/IL-23 Antibody
, ClinicalTrials -Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Interleukin-1 -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study, Ann Rheum Dis. 1 avr, vol.71, issue.4, pp.563-569, 2012. ,
Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease, 2016. ,
Announces Results From Phase 3 EYEGUARD(TM)-B Study, 2016. ,
, , 2016.
, ClinicalTrials -Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD TM -B), 2016.
, Public summary of opinion on orphan designation Recombinant human monoclonal antibody to human interleukin (IL)-17A of the IgG1/k class for the treatment of chronic non-infectious uveitis, 2016.
Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology. avr, vol.120, issue.4, pp.777-87, 2013. ,
STem cells in retinal regeneration: past, present and future, Development. 15 juin, vol.140, issue.12, pp.2576-85, 2013. ,
Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients, Int J Rheum Dis. avr, vol.16, issue.2, pp.139-186, 2013. ,
Differentiation of marrow stromal cells into photoreceptors in the rat eye, J Neurosci Off J Soc Neurosci. 27 août, vol.23, issue.21, pp.7742-7751, 2003. ,
du parlement européen et du conseil du 16 décembre 1999 concernant les médicaments orphelins, 2000. ,
Translation of rare disease research into orphan drug development: disease matters, Drug Discov Today. déc, vol.14, pp.1166-73, 2009. ,
Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases, J Clin Epidemiol. avr, vol.61, issue.4, pp.324-354, 2008. ,
, Méthodologie des essais cliniques de petits effectifs
, Patient's recruitment in clinical trials for rare diseases a strategy to anticipate, vol.108